Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Dana J. Nickens"'
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 9, Pp 1256-1267 (2022)
Abstract Dacomitinib is a second‐generation, irreversible EGFR tyrosine kinase inhibitor for first‐line treatment of patients with metastatic non‐small cell lung cancer and EGFR‐activating mutations. A high rate of dose reductions in the pivo
Externí odkaz:
https://doaj.org/article/4fcbce04e2f44d3b8e2ad4ce90dfa420
Autor:
Weiwei Tan, Kourosh Parivar, Keith D. Wilner, Michael Amantea, Reza Khosravan, Akintunde Bello, Dana J. Nickens, Erjian Wang
Supplementary Table and Development of the population PK model
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c63f2ef81252a959212330340b58133
https://doi.org/10.1158/1078-0432.22467297.v1
https://doi.org/10.1158/1078-0432.22467297.v1
Autor:
Weiwei Tan, Kourosh Parivar, Keith D. Wilner, Michael Amantea, Reza Khosravan, Akintunde Bello, Dana J. Nickens, Erjian Wang
Purpose: We assessed the effect of baseline patient demographic and disease characteristics on the crizotinib pharmacokinetic parameters oral clearance (CL/F), volume of distribution (V2/F), and area under the curve at steady state (AUCss) following
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a06274236be1b2a0878cdd6cd60f0f8
https://doi.org/10.1158/1078-0432.c.6526605.v1
https://doi.org/10.1158/1078-0432.c.6526605.v1
Autor:
Margherita Bennetts, Michael Moran, Maik Häntschel, Julia Brinkmann, Kato Kambartel, Barbara Melosky, Federico Cappuzzo, Antonin Kayser, Dana J. Nickens
Publikováno v:
Molecular Diagnosis & Therapy
Background Identification of variable epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer (NSCLC) is important for the selection of appropriate targeted therapies. This meta-analysis was conducted to provide a worldwi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95b831daf22595ee83f903bc2807b019
http://europepmc.org/articles/PMC8766385
http://europepmc.org/articles/PMC8766385
Publikováno v:
Oncology and Therapy
Introduction Dacomitinib and gefitinib are irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) indicated for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) and EGFR-activating m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e2083dcde6cca523a60f14fb46c40ae
https://doi.org/10.1007/s40487-021-00156-2
https://doi.org/10.1007/s40487-021-00156-2
Publikováno v:
Future Oncology. 15:3987-4001
Aim: To evaluate how efficacy outcomes from real-world data (RWD) can support those from randomized controlled trials (RCTs), in the context of first-line tyrosine kinase inhibitor treatment of metastatic renal cell carcinoma. Patients & methods: Pub
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1970a830bf9f611465adf1710212d627
https://doi.org/10.2217/fon-2019-0421
https://doi.org/10.2217/fon-2019-0421
Autor:
Arial Desscan, Katherine Adcock, Kate Fife, Meg Bennetts, Michael Moran, Natalie Charnley, Dana J. Nickens
Publikováno v:
Targeted Oncology
Background Randomized controlled trials (RCTs) have stringent inclusion criteria and may not fully represent patients seen in everyday clinical practice. Real-world data (RWD) can provide supportive evidence for the effectiveness of medical intervent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::008c71e3b8e8c3200c57ec79da08826b
https://doi.org/10.1007/s11523-019-00653-5
https://doi.org/10.1007/s11523-019-00653-5
Autor:
Dana J. Nickens, Jerry Li, Jennifer E. Hibma, Akash Khandelwal, Swan Li, Carlo L. Bello, Yulia Vugmeyster
Publikováno v:
Cancer Research. 81:1362-1362
BACKGROUND: Avelumab, a monoclonal antibody targeting PD-L1, was recently approved in the United States for first-line maintenance (1LM) treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c0d9124e99e5517f68f65b6b5f57dee
https://doi.org/10.1158/1538-7445.am2021-1362
https://doi.org/10.1158/1538-7445.am2021-1362
Autor:
Ana Ruiz-Garcia, Jerry Li, Akash Khandelwal, Dana J. Nickens, Swan Lin, Carlo L. Bello, Yulia Vugmeyster
Publikováno v:
Cancer Research. 81:1361-1361
BACKGROUND Avelumab is a human IgG1 monoclonal antibody targeting PD-L1 that is approved in the US for second-line locally advanced or metastatic urothelial carcinoma (UC) and first-line maintenance (1LM) treatment of patients with UC that has not pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bae00c66934a42e1c551545fcb71b810
https://doi.org/10.1158/1538-7445.am2021-1361
https://doi.org/10.1158/1538-7445.am2021-1361
Publikováno v:
Cancer Research. 81:1360-1360
BACKGROUND: Avelumab is a human IgG1 monoclonal antibody targeting PD-L1 that is approved in the US for second-line locally advanced or metastatic urothelial carcinoma (UC) and first-line maintenance (1LM) treatment of patients with UC that has not p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::508d392b90062db8e2153c83b6f4a504
https://doi.org/10.1158/1538-7445.am2021-1360
https://doi.org/10.1158/1538-7445.am2021-1360